Distribution of aPL in patients with scleroderma and controls
| Scleroderma | Limited | Diffuse | Controls | |
|---|---|---|---|---|
| (n = 25) | (n = 18) | (n = 7) | (n = 100) | |
| Any aPL | 8 | 6 | 2 | 5 |
| aCL | 6 | 5 | 1 | 5 |
| IgG | 4 | 3 | 1 | 3 |
| IgM | 2 | 2 | 0 | 2 |
| Anti-β2GPI | 2 | 2 | 0 | 3 |
| IgG | 1 | 1 | 0 | 2 |
| IgM | 1 | 1 | 0 | 1 |
| aPS-PT | 3 | 2 | 1 | 0 |
| IgG | 0 | 0 | 0 | 0 |
| IgM | 3 | 2 | 1 | 0 |